Floatz logo

AZD-1386

Chronic Pain

AstraZenecaSmall moleculePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

101 Active assets in the Chronic Pain cohort.

Asset / SponsorPhaseRating
(±)-TRAMADOL
EMS
Phase 4BBB
METHADONE
Cari Health Inc.
Phase 4BBB
LIDOCAINE
National and Kapodistrian University of Athens
Phase 4BBB
NEPENTHE
Bursa City Hospital
Phase 4BBB
FENTANYL
Aga Khan University
Phase 4BBB

View all 50 →

Same molecule, other indications

AZD-1386 is also rated in:

PainDormant
CCC
Indicative ·
53 / 100
View asset →
neuralgiaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →